There is strong evidence that the amyloid-beta peptide (Aβ) plays a central role in the pathogenesis of Alzheimer's disease (AD). In this context, a detailed quantitative description of the interactions with different Aβ species is essential for characterization of physiological and artificial ligands. However, the high aggregation propensity of Aβ in concert with its susceptibility to structural changes due to even slight changes in solution conditions has impeded surface plasmon resonance (SPR) studies with homogeneous Aβ conformer species. Here, we have adapted the experimental procedures to state-of-the-art techniques and established novel approaches to reliably overcome the aforementioned challenges. We show that the application of density gradient centrifugation (DGC) for sample purification and the use of a single chain variable fragment (scFv) of a monoclonal antibody directed against the amino-terminus of Aβ allows reliable SPR measurements and quality control of the immobilized Aβ aggregate species at any step throughout the experiment.
References
[1]
Gulland A (2012) Number of people with dementia will reach 65.7 million by 2030, says report. Bmj 344: e2604. doi: 10.1136/bmj.e2604
[2]
Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nature medicine 10 Suppl: S10–17. doi: 10.1038/nm1066
[3]
Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545–555. doi: 10.1016/j.cell.2005.02.008
[4]
Schmidt ML, DiDario AG, Otvos L Jr, Hoshi N, Kant JA, et al. (1994) Plaque-associated neuronal proteins: a recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer's disease brain. Experimental neurology 130: 311–322. doi: 10.1006/exnr.1994.1209
[5]
Milligan CE (2000) Caspase cleavage of APP results in a cytotoxic proteolytic peptide. Nature medicine 6: 385–386.
[6]
Xia N, Liu L, Harrington MG, Wang J, Zhou F (2010) Regenerable and simultaneous surface plasmon resonance detection of abeta(1–40) and abeta(1–42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody. Analytical chemistry 82: 10151–10157. doi: 10.1021/ac102257m
[7]
Wang-Dietrich L, Funke SA, Kühbach K, Wang K, Besmehn A, et al. (2013) The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. Journal of Alzheimer's disease: JAD 34: 985–994.
[8]
Stravalaci M, Bastone A, Beeg M, Cagnotto A, Colombo L, et al. (2012) Specific recognition of biologically active amyloid-beta oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. The Journal of biological chemistry 287: 27796–27805. doi: 10.1074/jbc.m111.334979
[9]
Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, et al. (2013) Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Analytical biochemistry 433: 112–120. doi: 10.1016/j.ab.2012.09.014
[10]
Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, et al. (2013) Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Annals of neurology 73: 104–119. doi: 10.1002/ana.23748
[11]
Finder VH, Glockshuber R (2007) Amyloid-beta aggregation. Neuro-degenerative diseases 4: 13–27. doi: 10.1159/000100355
[12]
Stenberg E, Persson B, Roos H, Urbaniczky C (1991) Quantitative-Determination of Surface Concentration of Protein with Surface-Plasmon Resonance Using Radiolabeled Proteins. J Colloid Interf Sci 143: 513–526. doi: 10.1016/0021-9797(91)90284-f
[13]
Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, et al. (2006) Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1–42Arctic and A beta 1–42wt. The FEBS journal 273: 2618–2630. doi: 10.1111/j.1742-4658.2006.05263.x
[14]
Wood SJ, Maleeff B, Hart T, Wetzel R (1996) Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. Journal of molecular biology 256: 870–877. doi: 10.1006/jmbi.1996.0133
[15]
Nagel-Steger L, Demeler B, Meyer-Zaika W, Hochdorffer K, Schrader T, et al. (2010) Modulation of aggregate size- and shape-distributions of the amyloid-beta peptide by a designed beta-sheet breaker. European biophysics journal: EBJ 39: 415–422. doi: 10.1007/s00249-009-0416-2
[16]
Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG (2006) Analyzing a kinetic titration series using affinity biosensors. Analytical biochemistry 349: 136–147. doi: 10.1016/j.ab.2005.09.034
[17]
Amijee H, Bate C, Williams A, Virdee J, Jeggo R, et al. (2012) The N-methylated peptide SEN304 powerfully inhibits Abeta(1–42) toxicity by perturbing oligomer formation. Biochemistry 51: 8338–8352. doi: 10.1021/bi300415v
[18]
Green NM (1963) Avidin. 1. The Use of (14-C)Biotin for Kinetic Studies and for Assay. The Biochemical journal 89: 585–591.
[19]
Glück JM, Koenig BW, Willbold D (2011) Nanodiscs allow the use of integral membrane proteins as analytes in surface plasmon resonance studies. Analytical biochemistry 408: 46–52. doi: 10.1016/j.ab.2010.08.028
[20]
Dornieden S, Müller-Schiffmann A, Sticht H, Jiang N, Cinar Y, et al. (2013) Characterization of a single-chain variable fragment recognizing a linear epitope of abeta: a biotechnical tool for studies on Alzheimer's disease? PloS one 8: e59820. doi: 10.1371/journal.pone.0059820
[21]
Müller-Schiffmann A, Marz-Berberich J, Andreyeva A, Ronicke R, Bartnik D, et al. (2010) Combining independent drug classes into superior, synergistically acting hybrid molecules. Angewandte Chemie 49: 8743–8746. doi: 10.1002/anie.201004437
[22]
Ford T, Graham J, Rickwood D (1994) Iodixanol: a nonionic iso-osmotic centrifugation medium for the formation of self-generated gradients. Analytical biochemistry 220: 360–366. doi: 10.1006/abio.1994.1350
[23]
Stine WB Jr, Snyder SW, Ladror US, Wade WS, Miller MF, et al. (1996) The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. Journal of protein chemistry 15: 193–203. doi: 10.1007/bf01887400
